Why the study?
Does inactivated poliovirus vaccine (IPV) provide better safety and comparable efficacy compared to oral poliovirus vaccine (OPV) for protection against paralytic poliomyelitis?
Does inactivated poliovirus vaccine (IPV) provide better safety and comparable efficacy compared to oral poliovirus vaccine (OPV) for protection against paralytic poliomyelitis?
IPV is recommended over OPV due to its superior safety profile and comparable or better efficacy in inducing long-lasting immunity.
Answers are grounded in this paper and cite their sources.
IPV may be preferred for routine immunization due to safety; leaves open optimal strategies for global eradication.
Inactivated poliovirus vaccine (IPV) is the vaccine of choice for protection against paralytic poliomyelitis provided that it is used within the context of a program to increase and sustain the level of uptake to as close to 100% as possible. This means targeting the disadvantaged in society as well as those who have their own pediatrician. The reasons are that enhanced-potency killed polio vaccine is safe, whereas oral poliovirus vaccine (OPV) is associated with a low, but definite, risk of paralysis, especially after the first dose. The immunity, as measured by antibody concentrations, is at least as good as and, in some circumstances, such as in the tropics or for booster doses, better than that provided by OPV. IPV reduces the replication of living poliovirus and produces herd immunity, as exemplified by experience in Sweden and Holland. The immunity, whether induced by OPV or IPV, involves memory cells and is long lasting, as seen by the rapid secondary response to a booster dose. IPV also can be mixed with other vaccine components to provide immunity against an increasing range of childhood infections.
No takes yet. Share an insight, caveat, or question.
A. J. Beale (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: